<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02061020</url>
  </required_header>
  <id_info>
    <org_study_id>AOR12144 / P111114</org_study_id>
    <secondary_id>2013-A00245-40</secondary_id>
    <nct_id>NCT02061020</nct_id>
  </id_info>
  <brief_title>Study of the Relationship Between Dose-concentration-effect of Delta-9-tetrahydrocannabinol (THC) and the Ability to Drive in Chronic or Occasional Cannabis Users</brief_title>
  <acronym>VIGICANN</acronym>
  <official_title>Pilot Study of the Relationship Between Dose-concentration-effect of Delta-9-tetrahydrocannabinol and the Ability to Drive in Chronic or Occasional Cannabis Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the effects of smoked cannabis consumption on performance on a driving simulator and&#xD;
      reaction time. The study aims to explore the relationship between concentrations of cannabis&#xD;
      in the blood, driving performance and reaction time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine:&#xD;
&#xD;
        -  The relationship between THC blood levels and driving performance measured on a York&#xD;
           Driving simulator&#xD;
&#xD;
        -  The relationship between THC blood levels and reaction times as measured on the&#xD;
           psychomotor vigilance test (PVT)&#xD;
&#xD;
        -  the pharmacokinetics of THC in occasional and chronic cannabis consumers&#xD;
&#xD;
        -  Determine the minimum blood concentration level of THC and 11-OH-THC, below which no&#xD;
           effect of cannabis is observed&#xD;
&#xD;
        -  Determine whether the polymorphism of CYP2C9 (* 3) is associated with the AUC, Cmax, and&#xD;
           higher THC T1/2&#xD;
&#xD;
        -  Determine if the polymorphism of CYP2C9 (* 3) is associated with different&#xD;
           pharmacodynamic effects at a given THC level on performance measured by driving&#xD;
           simulation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to drive a motor vehicle measured using a driving simulator</measure>
    <time_frame>0h, 1h, 2h, 4h, 6h, 8h, 12h and 24 h</time_frame>
    <description>The association between THC blood concentrations and driving performances as measured by deviations from the centre of the road and variations of speed at 0h, 1h, 2h, 4h, 6h, 8h, 12h and 24 h after smoking.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychomotor Vigilance Test (PVT) measures</measure>
    <time_frame>0h, 1h, 2h, 4h, 6h, 8h, 12h et 24h</time_frame>
    <description>The association between THC blood concentration and impaired reaction time on PVT measured sequentially over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>THC pharmacokinetics of occasional and chronic users over 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>THC pharmacokinetics parameters (AUC, T1/2, CMAX) of occasional and chronic users over 24 hours will be modelled using a population nonlinear mixed approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hoursTHC pharmacokinetics (AUC, T1 / 2, CMAX) and its relationships with genotype CYP2C9 * 3</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hoursTHC pharmacokinetics (AUC, T1 / 2, CMAX) and its relationships with genotype CYP2C9 * 3</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Occasional (1-2 Joints Per Week) and Chronic (1-2 Joints Per Day) Cannabis Users</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>THC containing cigarettes 10mg&#xD;
THC containing cigarettes 30mg&#xD;
Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>THC containing cigarettes 30mg&#xD;
Placebo&#xD;
THC containing cigarettes 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo&#xD;
THC containing cigarettes 10mg&#xD;
THC containing cigarettes 30mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis (THC) in cigarettes of 30mg, 10mg and placebo</intervention_name>
    <description>Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.&#xD;
Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.&#xD;
Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).&#xD;
Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Healthy volunteer of male gender from 18 to 25 years&#xD;
&#xD;
          -  Normal medical examination&#xD;
&#xD;
          -  Driving license owner&#xD;
&#xD;
          -  BMI between 18.5 and 25&#xD;
&#xD;
          -  moderate tobacco consumption&#xD;
&#xD;
          -  moderate consumption of coffee, tea, cola (≤ 225mg caffeine per day)&#xD;
&#xD;
          -  Cannabis user for at least 1 year&#xD;
&#xD;
          -  Occasional (1-2 joints per week) or chronic (1-2 joints per day) cannabis consumers&#xD;
&#xD;
          -  Availability during the study&#xD;
&#xD;
          -  Signed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Participation in another clinical study&#xD;
&#xD;
          -  Having taken any psychotropic medication in the past one month&#xD;
&#xD;
          -  Having taken any narcotic (alcohol, psychotropic drugs, other narcotics) other than&#xD;
             THC in the past 3 days (negative urinary test at inclusion)&#xD;
&#xD;
          -  Alcohol blood level positive at inclusion&#xD;
&#xD;
          -  Excessive alcohol consumption (AUDIT score &gt; 7)&#xD;
&#xD;
          -  Dependence, present or past, to any psychotropic product (alcohol, psychoactive drugs,&#xD;
             other narcotic)&#xD;
&#xD;
          -  Depression&#xD;
&#xD;
          -  Sleep disorders&#xD;
&#xD;
          -  Any psychiatric history, including psychosis&#xD;
&#xD;
          -  Deprived of their liberty by judicial or administrative decision&#xD;
&#xD;
          -  Lack of medical insurance&#xD;
&#xD;
          -  Professional use of motorized vehicles&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Hartley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sleep Disorders Unit - Raymond Poincaré Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Raymond Poincare Hospital</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <last_update_submitted>June 8, 2016</last_update_submitted>
  <last_update_submitted_qc>June 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>delta-9-tetrahydrocannabinol, volunteers, cannabis users</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

